Alinamin F10 injections 10 mg (fursultiamine, prosultiamine)
Brand : Japan Supplements
Product Code :
Availability : 12
General information on Japanese Alinamin F10 injections 10 mg (fursultiamine, prosultiamine)
Package details: 50 vials
Manufacturer: Teva Takeda Yakuhin Ltd., Japan
Active ingredient: fursultiamine (chemical formula C17H26N4O3S2), prosultiamine (chemical formula C15H24N4O2S2)
Medical effect: Alinamin-F injections are effective for the treatment of the following diseases and conditions:
- vitamin B1 deficiency,
- insufficient intake of vitamin B1 due to specific conditions (depletion disease, hyperthyroidism, pregnant women, lactating women etc.),
- Wernicke's encephalopathy,
- neuralgia, muscle pain or joint pain associated with vitamin B1 deficiency.
Contraindications and precautions: if an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.
Dosage and administration of Alinamin F10 injections 10 mg from Japan (fursultiamine, prosultiamine)
In general, for adults, take intravenously 1 ampoule a day. The dosage may be adjusted by the consulting doctor according to age and symptoms.
How effective are Alinamin F10 injections 10 mg from Japan (fursultiamine, prosultiamine)?
Japanese Alinamin-F injections contain two active ingredients: fursultiamine and prosultiamine, both disulfide derivatives of thiamine. Its lipid solubility is better than thiamine and the medicine does not depend on intestinal transporters for absorption. In other words, Alinamin F10 injections are more readily utilized in the body than natural vitamin B1.
Who should take Alinamin F10 injections 10 mg from Japan?
Alinamin F10 injections are effective for the treatment of thiamine (vitamin B1) deficiency and the related diseases and symptoms, including neuralgia, muscle and joint pain and the heart failure from beriberi. Also, it can be used for the chronic myelopathy characterized by motor dysfunction of the lower extremities (T. Nakamura, T. Matsuo et al. “Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: results from an open-label clinical trial”. BMC Medicine, volume 11, 182 (2013)).